Literature DB >> 21111405

Aberrant ROCK activation promotes the development of type I diabetes in NOD mice.

Partha S Biswas1, Sanjay Gupta, Emily Chang, Govind Bhagat, Alessandra B Pernis.   

Abstract

Aberrant production of IL-21 by T cells is critical for the development of type 1 diabetes (T1D) in NOD mice. The pathogenic effects of IL-21 are partly due to its ability to promote the generation of T(H)-17 cells. Interferon Regulatory Factor (IRF4) is a crucial regulator of IL-17 and IL-21 production. We recently found that the serine-threonine kinase ROCK2 phosphorylates IRF4 and regulates its ability to control IL-17 and IL-21 production. Here we show that NOD T cells aberrantly activate ROCK2. We furthermore demonstrate that ROCK inhibition corrects the abnormal IRF4 function in NOD T cells and diminishes their production of IL-17 and IL-21. Importantly, administration of a ROCK inhibitor to NOD mice protects against diabetes development. These studies thus support the idea that ROCK2 is inappropriately activated in NOD T cells and that ROCK kinases could represent important therapeutic targets for the treatment of T1D.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21111405      PMCID: PMC3031108          DOI: 10.1016/j.cellimm.2010.10.009

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  24 in total

1.  The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4.

Authors:  Anne Brüstle; Sylvia Heink; Magdalena Huber; Christine Rosenplänter; Christine Stadelmann; Philipp Yu; Enrico Arpaia; Tak W Mak; Thomas Kamradt; Michael Lohoff
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

Review 2.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

3.  A method for measuring Rho kinase activity in tissues and cells.

Authors:  Ping-Yen Liu; James K Liao
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

4.  IL-17 immunity in human type 1 diabetes.

Authors:  Jarno Honkanen; Janne K Nieminen; Ru Gao; Kristiina Luopajarvi; Harri M Salo; Jorma Ilonen; Mikael Knip; Timo Otonkoski; Outi Vaarala
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

Review 5.  The NOD mouse: a model of immune dysregulation.

Authors:  Mark S Anderson; Jeffrey A Bluestone
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

6.  A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

Authors:  Yuichi Kikuchi; Muneharu Yamada; Toshihiko Imakiire; Taketoshi Kushiyama; Keishi Higashi; Naomi Hyodo; Kojiro Yamamoto; Takashi Oda; Shigenobu Suzuki; Soichiro Miura
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

7.  RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease.

Authors:  Fangfang Peng; Dongcheng Wu; Bo Gao; Alistair J Ingram; Baifang Zhang; Katherine Chorneyko; Rick McKenzie; Joan C Krepinsky
Journal:  Diabetes       Date:  2008-03-20       Impact factor: 9.461

8.  The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.

Authors:  Atsushi Gojo; Kazunori Utsunomiya; Kanta Taniguchi; Tamotsu Yokota; Shoh Ishizawa; Yasushi Kanazawa; Hideaki Kurata; Naoko Tajima
Journal:  Eur J Pharmacol       Date:  2007-04-20       Impact factor: 4.432

9.  Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.

Authors:  Vasantha Kolavennu; Lixia Zeng; Hui Peng; Yin Wang; Farhad R Danesh
Journal:  Diabetes       Date:  2007-12-14       Impact factor: 9.461

10.  Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production.

Authors:  Renu Jain; Danielle M Tartar; Randal K Gregg; Rohit D Divekar; J Jeremiah Bell; Hyun-Hee Lee; Ping Yu; Jason S Ellis; Christine M Hoeman; Craig L Franklin; Habib Zaghouani
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  5 in total

1.  Haploinsufficiency of interferon regulatory factor 4 strongly protects against autoimmune diabetes in NOD mice.

Authors:  Satoru Akazawa; Masakazu Kobayashi; Genpei Kuriya; Ichiro Horie; Liping Yu; Hironori Yamasaki; Minoru Okita; Yuji Nagayama; Toshifumi Matsuyama; Masoud Akbari; Katsuyuki Yui; Atsushi Kawakami; Norio Abiru
Journal:  Diabetologia       Date:  2015-08-14       Impact factor: 10.122

Review 2.  ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

Authors:  Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Clin Immunol       Date:  2021-08-14       Impact factor: 10.190

3.  Homeostasis of IL-15 dependent lymphocyte subsets in the liver.

Authors:  Yuneivy Cepero-Donates; Volatiana Rakotoarivelo; Marian Mayhue; Averil Ma; Yi-Guang Chen; Sheela Ramanathan
Journal:  Cytokine       Date:  2016-01-05       Impact factor: 3.861

4.  Structure of Shroom domain 2 reveals a three-segmented coiled-coil required for dimerization, Rock binding, and apical constriction.

Authors:  Swarna Mohan; Ryan Rizaldy; Debamitra Das; Robert J Bauer; Annie Heroux; Michael A Trakselis; Jeffrey D Hildebrand; Andrew P VanDemark
Journal:  Mol Biol Cell       Date:  2012-04-04       Impact factor: 4.138

5.  The interaction between Shroom3 and Rho-kinase is required for neural tube morphogenesis in mice.

Authors:  Debamitra Das; Jenna K Zalewski; Swarna Mohan; Timothy F Plageman; Andrew P VanDemark; Jeffrey D Hildebrand
Journal:  Biol Open       Date:  2014-08-29       Impact factor: 2.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.